Latest Share Purchase Plan News

Arizona Lithium has secured A$8 million through the sale of its Big Sandy Lithium Project and Lithium Research Center, sharpening its focus on the Prairie Lithium Project in Canada, which is closer to production.

BetMakers Technology Group has successfully closed an oversubscribed Share Purchase Plan, boosting its total capital raise to $13.7 million alongside a recent placement. The funds will support debt repayment, strategic acquisitions, and operational growth.

Orion Minerals has raised approximately A$5.8 million through a share placement and loan conversions, while launching a Share Purchase Plan targeting an additional A$4 million to fund key copper projects.

EQ Resources has successfully raised A$4 million through a strongly supported placement to fund expansion and optimization at its Mt Carbine tungsten mine, reinforcing its position amid global supply challenges.

QPM Energy Limited has launched a $2 million Share Purchase Plan at $0.031 per share, matching a recent $10 million placement, to support the development of its Isaac Energy Hub. Eligible shareholders in Australia and New Zealand can participate until mid-July.

TruScreen Group Limited has corrected an administrative error in its Share Purchase Plan allocations, ensuring shareholders receive their proper pro-rata entitlements ahead of a key special meeting.

S2 Resources has closed its Share Purchase Plan significantly oversubscribed, prompting a pro-rata scale back. The combined funds from the SPP and recent placement will accelerate exploration across multiple Australian projects.

Aguia Resources has successfully closed its Share Purchase Plan, raising approximately $649,200 through the issuance of over 18 million new shares. This capital injection supports the company’s phosphate and gold projects in Brazil and Colombia.

Blackstone Minerals has raised $22.6 million through a heavily oversubscribed placement led by Macquarie Bank, fueling a major drilling program at its Mankayan Copper-Gold Project in the Philippines. The capital raise follows a transformative merger and signals strong institutional confidence in the company’s growth strategy.

Prescient Therapeutics has opened a Share Purchase Plan to raise up to $7 million, offering shareholders discounted shares to fund the Phase 2 development of its targeted cancer therapy PTX-100.

Staude Capital Global Value Fund Limited (GVF) has responded to ASX concerns over a media article revealing details of its capital raising before official announcement, denying any direct media disclosures and reaffirming its compliance policies.

Prescient Therapeutics has launched a $7 million Share Purchase Plan at a notable discount to fund the next phase of clinical trials for its promising PTX-100 cancer therapy. The capital raise aims to accelerate progress toward regulatory approval and patient access.